MedPath

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

226

Active:12
Completed:72

Trial Phases

5 Phases

Phase 1:33
Phase 2:75
Phase 3:55
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (212 trials with phase data)• Click on a phase to view related trials

Phase 2
75 (35.4%)
Phase 3
55 (25.9%)
Not Applicable
48 (22.6%)
Phase 1
33 (15.6%)
Phase 4
1 (0.5%)

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Phase 2
Not yet recruiting
Conditions
Metastatic/Locally Advanced Small-Cell Lung Cancer
Metastatic/Locally Advanced Poorly Differentiated NEC
Metastatic/Locally Advanced High-grade MTC
Interventions
First Posted Date
2025-06-11
Last Posted Date
2025-06-11
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
40
Registration Number
NCT07016230
Locations
🇫🇷

Gustave Roussy, Villejuif, France

Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood

Not Applicable
Not yet recruiting
Conditions
Ototoxicity, Drug-Induced
Ototoxicity, Radiation-Induced
Pediatric Cancer
First Posted Date
2025-05-04
Last Posted Date
2025-05-04
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
500
Registration Number
NCT06957132
Locations
🇫🇷

Hôpital Necker, Paris, France

🇫🇷

Institut Curie, Paris, France

🇫🇷

Gustave Roussy, Villejuif, France

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Phase 4
Not yet recruiting
Conditions
Kidney Cancer
Renal Cell Cancer
Interventions
First Posted Date
2025-04-18
Last Posted Date
2025-04-18
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
50
Registration Number
NCT06934057
Locations
🇫🇷

Institut de Cancérologie de l'Ouest - Angers, Angers, France

🇫🇷

Centre Georges François Leclerc, Dijon, France

🇫🇷

Centre Léon Bérard, Lyon, France

and more 4 locations

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

Not Applicable
Not yet recruiting
Conditions
Risk of Breast Cancer
Risk of Colorectal Cancer
Risk of Upper Gastrointestinal Cancers
Risk of Hepatic Cancers
Risk of Lung Cancer
Risk of Skin Cancers Except Basal-cell Carcinomas
Risk of Head and Neck Cancers
Risk of Mesothelioma
Risk of Gynaecological Cancer
Risk of Kidney Cancer
First Posted Date
2025-04-02
Last Posted Date
2025-04-13
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
5909
Registration Number
NCT06907095
Locations
🇫🇷

Gustave Roussy, Villejuif, France

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 46
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath